On April 1, 2019 Rgenix, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, reported that Isabel Kurth, Ph.D., Vice President of Research at Rgenix, will present an abstract about Rgenix’s RGX-019 program at the 2019 American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting (Press release, Rgenix, APR 1, 2019, View Source [SID1234534849]). The meeting is scheduled to take place Friday, March 29 through Wednesday, April 3 in Atlanta.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The details of Rgenix’s presentation are as follows:

Event:
AACR Annual Meeting 2019

Date: April 3, 2019

Time: 8:00 A.M. – 12:00 P.M. EST

Description: Abstract LB-277/23, "Characterization of the anti-cancer and immunologic activity of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor"

Location: Section 40, Georgia World Congress Center, 285 Andrew Young International Blvd
NW, Atlanta, GA 30313

Dr. Kurth will present data from pre-clinical research of RGX-019, a novel pre-clinical stage humanized monoclonal antibody targeting the MERTK receptor.